Adamax Research Evidence
The Adamax evidence base: trials, journals, and what the data does not yet show.
Parent Compound Evidence: Semax
Direct clinical data on Adamax does not exist — all human inference is extrapolated from the parent Semax compound. Semax was shown to bind specifically to membrane-associated sites in rat basal forebrain with a dissociation constant of 2.4 ± 1.0 nM. A single intranasal application at 50 μg/kg produced rapid increases in BDNF protein levels in the basal forebrain, alongside ~3-fold increases in exon III BDNF mRNA and ~2-fold increases in TrkB mRNA. Treated animals showed increased conditioned avoidance reactions. Adamax is studied within this framework to assess how the adamantyl modification alters these neurotrophin interactions. [Dolotov et al., 2006]
Regulatory and Legal Status
Adamax has no FDA-approved indication and is not approved for human use. It is sold exclusively as a research-grade compound. Notably, Adamax has been intercepted at the border as an unapproved designer peptide in New Zealand. In June 2025, New Zealand's Medicines Classification Committee received a submission recommending Adamax be classified as a prescription medicine. Researchers and users should verify the legal status in their jurisdiction prior to purchase or use. It is not listed on the WADA 2026 Prohibited List, but competitive athletes should verify via GlobalDRO.com before any research use.
Research Limitations
All mechanistic data for Adamax is derived from preclinical animal studies, primarily on the parent Semax compound rather than Adamax itself. No randomized controlled trial, phase 1 clinical trial, or published human pharmacokinetic data exists for Adamax as of mid-2026. The adamantane modification's actual effect on blood-brain barrier penetration in humans remains unconfirmed. The compound's effects, safety profile, and long-term consequences in humans are entirely unknown. This is educational information, not medical advice.